Goldman Sachs’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Goldman Sachs’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$629K	Buy	18,646 +11,464	+160%	+$344K	﹤0.01%	5559
2026 Q1	$209K	Buy	+7,182	New	+$208K	﹤0.01%	6064
2023 Q3	–	Sell	-11,730	Closed	-$274K	–	5694
2023 Q2	$274K	Hold	11,730	–	–	﹤0.01%	5056
2023 Q1	$273K	Sell	11,730 -9,719	-45%	-$243K	﹤0.01%	5163
2022 Q4	$540K	Buy	21,449 +9,719	+83%	+$261K	﹤0.01%	4825
2022 Q3	$310K	Sell	11,730 -38,354	-77%	-$1.18M	﹤0.01%	5284
2022 Q2	$1.45M	Buy	50,084 +38,354	+327%	+$1.14M	﹤0.01%	4325
2022 Q1	$404K	Hold	11,730	–	–	﹤0.01%	5470
2021 Q4	$514K	Buy	+11,730	New	+$555K	﹤0.01%	5364

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's IDNA Position: Q2 2026 in Review

Goldman Sachs increased its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 160% in Q2 2026, buying an estimated $344K and bringing the position to 18,646 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #5559.

Goldman Sachs first reported a position in IDNA in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.45M in Q2 2022. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Goldman Sachs held 18,646 shares of iShares Genomics Immunology and Healthcare ETF worth $629K as of Q2 2026.
Goldman Sachs bought 11,464 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $344K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5559 holding.
Goldman Sachs first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and has held it in 9 quarters since.
Goldman Sachs's iShares Genomics Immunology and Healthcare ETF position peaked at $1.45M in Q2 2022.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.